La cadena de opciones muestra datos clave de las opciones de acciones de Usana Health Sciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Usana Health Sciences..

Usana Health Sciences (NYSE:USNA) Bolsa, Cadena de Opciones

USANA HEALTH SCIENCES INC

Usana Health Sciences

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

Usana Health Sciences Inc

WIIM

USNA

Usana Health Sciences shares are trading higher after the company reported Q1 financial results and beat its adjusted EPS and sales estimates.

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.71 by 2.82 percent. This is a 15.12 percent decrease over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $249.54 million which beat the analyst consensus estimate of $243.04 million by 2.67 percent. This is a 9.54 percent increase over sales of $227.80 million the same period last year.

Earnings

Earnings Beats

News

Usana Health Sciences Q1 Adj. EPS $0.73 Beats $0.71 Estimate, Sales $249.54M Beat $243.04M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) is estimated to report quarterly earnings at $4.36 per share on revenue of $976.14 million. 
• Herc Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>) is expected to report quarterly earnings at $2.21 per share on revenue of $847.18 million. 
• Peoples Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBO#NASDAQ">PEBO</a>) is expected to report quarterly earnings at $0.73 per share on revenue of $113.55 million. 
• Mercantile Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBWM#NASDAQ">MBWM</a>) is likely to report quarterly earnings at $1.19 per share on revenue of $57.70 million. 
• Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) is expected to report quarterly earnings at $6.34 per share on revenue of $17.79 billion. 
• Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) is likely to report quarterly earnings at $1.85 per share on revenue of $1.95 billion. 
• RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $19.79 billion. 
• Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) is estimated to report quarterly earnings at $1.15 per share on revenue of $33.23 billion. 
• Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) is estimated to report quarterly earnings at $3.54 per share on revenue of $1.88 billion. 
• Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) is estimated to report quarterly earnings at $1.89 per share on revenue of $4.88 billion. 
• Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) is estimated to report quarterly earnings at $1.68 per share on revenue of $5.83 billion. 
• Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) is estimated to report quarterly earnings at $1.01 per share on revenue of $988.89 million. 
• Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) is expected to report quarterly earnings at $2.15 per share on revenue of $2.63 billion. 
• Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) is estimated to report quarterly earnings at $0.60 per share on revenue of $5.28 billion. 
• MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) is projected to report quarterly earnings at $3.91 per share on revenue of $744.21 million. 
• Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) is projected to report quarterly earnings at $6.26 per share on revenue of $9.93 billion. 
• 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) is expected to report quarterly earnings at $1.77 per share on revenue of $5.75 billion. 
• Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) is projected to report quarterly earnings at $1.40 per share on revenue of $1.42 billion. 
• PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) is expected to report quarterly earnings at $2.42 per share on revenue of $3.82 billion. 
• GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) is estimated to report quarterly earnings at $1.26 per share on revenue of $9.00 billion. 
• Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) is projected to report quarterly earnings at $11.38 per share on revenue of $46.29 billion. 
• Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $4.56 billion. 
• Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is expected to report quarterly earnings at $1.64 per share on revenue of $5.58 billion. 
• Lotus Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) is estimated to report earnings for its fourth quarter. 
• United Community Banks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCB#NYSE">UCB</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $247.09 million. 
• Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $1.11 billion. 
• Iridium Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) is estimated to report quarterly earnings at $0.28 per share on revenue of $211.78 million. 
• Hope Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $114.97 million. 
• Dime Community Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $105.70 million. 
• Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) is estimated to report quarterly earnings at $0.43 per share on revenue of $478.24 million. 
<h3>Companies Reporting After The Bell</h3>
• SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) is expected to report quarterly earnings at $1.42 per share on revenue of $9.07 billion. 
• Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) is projected to report quarterly earnings at $3.75 per share on revenue of $10.06 billion. 
• Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) is estimated to report quarterly earnings at $3.22 per share on revenue of $11.22 billion. 
• Orrstown Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORRF#NASDAQ">ORRF</a>) is estimated to report quarterly earnings at $0.93 per share on revenue of $54.62 million. 
• Pathward Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) is expected to report quarterly earnings at $2.78 per share on revenue of $259.27 million. 
• First Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRBA#NASDAQ">FRBA</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $32.78 million. 
• Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $170.28 million. 
• Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $4.24 billion. 
• Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) is estimated to report quarterly earnings at $1.73 per share on revenue of $2.19 billion. 
• EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) is likely to report quarterly earnings at $0.91 per share on revenue of $2.00 billion. 
• Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) is estimated to report quarterly earnings at $2.22 per share on revenue of $2.12 billion. 
• PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) is expected to report quarterly earnings at $2.82 per share on revenue of $517.92 million. 
• PennyMac Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $92.33 million. 
• QCR Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) is expected to report quarterly earnings at $1.51 per share on revenue of $94.26 million. 
• Hanmi Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $63.43 million. 
• Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is likely to report quarterly earnings at $1.03 per share on revenue of $123.82 million. 
• Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $357.20 million. 
• Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) is likely to report quarterly earnings at $0.48 per share on revenue of $6.52 billion. 
• Zurn Elkay Water Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZWS#NYSE">ZWS</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $383.55 million. 
• Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $243.08 million. 
• Veritex Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBTX#NASDAQ">VBTX</a>) is expected to report quarterly earnings at $0.51 per share on revenue of $110.68 million. 
• Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) is expected to report quarterly earnings at $0.76 per share on revenue of $361.15 million. 
• First Busey (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $117.56 million. 
• West Fraser Timber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFG#NYSE">WFG</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $1.53 billion. 
• Weatherford International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) is likely to report quarterly earnings at $0.89 per share on revenue of $1.21 billion. 
• Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) is projected to report quarterly earnings at $0.89 per share on revenue of $803.02 million. 
• Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is expected to report quarterly earnings at $1.05 per share on revenue of $166.00 million. 
• National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $107.47 million. 
• Brandywine Realty Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDN#NYSE">BDN</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $119.45 million. 
• MIND Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $12.20 million. 
• Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) is estimated to report quarterly earnings at $1.13 per share on revenue of $273.47 million. 
• Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $195.35 million. 
• Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is estimated to report quarterly earnings at $0.46 per share on revenue of $22.46 billion. 
• East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) is expected to report quarterly earnings at $2.06 per share on revenue of $652.47 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BUSE

CASH

DCOM

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ENPH

EWBC

FRBA

HAFC

HOPE

IRDM

ISRG

MANH

MBWM

MCRI

MIND

MSCI

NBHC

NTRS

ORRF

PEBO

PEGA

PFSI

QCRH

RNST

STLD

TRMK

TSLA

VBTX

WFRD

Earnings Scheduled For April 22, 2025

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) will release its quarterly earnings report on Tuesday, 2025-04-22. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Usana Health Sciences to report an earnings per share (EPS) of $0.74.
The market awaits Usana Health Sciences's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.15, which was followed by a 3.91% increase in the share price the next day.
Here's a look at Usana Health Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.48</td>
<td>0.65</td>
<td>0.69</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.64</td>
<td>0.56</td>
<td>0.54</td>
<td>0.86</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>6.0%</td>
<td>-3.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745258496_0.png" alt="eps graph" />
<h3>Market Performance of Usana Health Sciences's Stock</h3>
Shares of Usana Health Sciences were trading at $23.74 as of April 18. Over the last 52-week period, shares are down 47.55%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Insights on Usana Health Sciences</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Usana Health Sciences.
Analysts have provided Usana Health Sciences with 1 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $36.0, suggesting a potential 51.64% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of and Honest Co, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Honest Co, with an average 1-year price target of $7.0, suggesting a potential 70.51% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for and Honest Co, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usana Health Sciences</td>
<td>Neutral</td>
<td>-3.38%</td>
<td>$175.06M</td>
<td>0.84%</td>
</tr>
<tr>
<td>Honest Co</td>
<td>Neutral</td>
<td>10.61%</td>
<td>$38.77M</td>
<td>-0.53%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Usana Health Sciences ranks higher in revenue growth compared to its peers. However, it lags behind in gross profit margin. The company's return on equity is also stronger than its peers. Overall, Usana Health Sciences is positioned favorably among its peers based on these key metrics.
<h3>Unveiling the Story Behind Usana Health Sciences</h3>
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
<h3>Usana Health Sciences's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Usana Health Sciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -3.38%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.1%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Usana Health Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of 0.84%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Usana Health Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 0.63%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Usana Health Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<a href="https://www.benzinga.com/quote/USNA/earnings">To track all earnings releases for Usana Health Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Usana Health Sciences's Earnings Expectations

SALT LAKE CITY, April 14, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, recently conducted a clinical study on its Celavive Resurfacing Serum to evaluate the efficacy and tolerance of the product. The results showed that Resurfacing Serum was well-tolerated by all subjects and users showed statistically significant improvements in the appearance of their skin in just two weeks.
"We are very pleased with the results of the Resurfacing Serum clinical study, and hope this will resonate well with our customer base," said Dr. Kathryn Armstrong, USANA's chief scientific officer. "Clinical studies are the best way to show the efficacy of a product, and the outcome of this study demonstrates the high quality of our Resurfacing Serum and USANA as a whole. As a company dedicated to science and quality, USANA invests a significant amount in research and development so it is imperative we provide our customers with the most effective products possible."
<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4404290-1&amp;h=1578398654&amp;u=https%3A%2F%2Faskthescientists.com%2Fqa%2Fresurfacing-serum-clinical-study%2F&amp;a=The+clinical+study">The clinical study</a>&nbsp;included 33 women with mild to moderate skin concerns, ranging between 39 and 65 years old with and average age of 56, and spanned different races and ethnicities.
Clinical skin measurements were taken before the participants began using Resurfacing Serum, and again after using the product for two, four, eight, and 12 weeks. The participants also completed a self-assessment questionnaire to evaluate how they felt about their skin after using the product.
Key findings of the study include:
<ul>
<li>Visible results in as little as four weeks</li>
<li>Over the 12-week course of the study, measurements showed a:
<ul>
<li>15.8% reduction in the appearance of fine lines</li>
<li>11.6% reduction in the appearance of pores</li>
<li>23% reduction in acute visible&nbsp;hyperpigmentation</li>
<li>8.9% improvement in the apparent clarity of the skin</li>
<li>8.6% improvement in the radiant appearance of the skin</li>
</ul>
</li>
<li>81.8% of participants reported it was the best their skin had felt in a long time</li>
<li>97% of participants would recommend the product</li>
</ul>
USANA's Resurfacing Serum is formulated to visibly transform the look of your skin with a powerful blend of alpha/beta hydroxy acids, niacinamide, peptides, and bakuchiol—a naturally-derived retinol alternative.
The unique combination of ingredients is unlike anything on the market in the way of efficacy and results. Upon application, it will help skin feel smoother and glowing. Long-term use will help reduce the appearance of dark spots and visible redness, while also improving fine lines and wrinkles.
&nbsp;

Clinical Study Shows USANA Health's Celavive Resurfacing Serum Enhances Skin Appearance in Just Two Weeks

ABEV

ANDE

BRBR

BRFS

CART

CASY

CELH

CENT

CENTA

COCO

COKE

COST

COTY

FIZZ

Fomento Economico Mexicano S.A.B. De C.V.

FRPT

HFFG

HNST

IPAR

ISPR

MDLZ

MGPI

MNST

PFGC

PSMT

SNYR

TBBB

UNFI

UPXI

USFD

WALD

WEST

Shares of consumer staple companies are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $38 to $36.

Price Target

Analyst Ratings

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $36

Usana Health Sciences shares are trading higher after the company reported better-than-expected Q4 financial results.

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is looking for FY2025 GAAP EPS of $1.50-$2.20 vs $2.73 analyst estimate..

Guidance

Usana Health Sciences Sees FY2025 GAAP EPS $1.50-$2.20 vs $2.73 Est

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is looking for FY2025 Adj EPS of $2.35-$3.00 vs $2.73 analyst estimate. sees sales of $920.000 million-$1.000 billion vs $934.51 million analyst estimate.

Usana Health Sciences Sees FY2025 Adj EPS $2.35-$3.00 vs $2.73 Est; Sees Sales $920.000M-$1.000B vs $934.51M Est

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.49 by 30.61 percent. This is a 26.44 percent decrease over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $213.61 million which beat the analyst consensus estimate of $208.84 million by 2.28 percent. This is a 3.38 percent decrease over sales of $221.08 million the same period last year.

Usana Health Sciences Q4 Adj $0.64 Beats $0.49 Estimate, Sales $213.61M Beat $208.84M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.&nbsp; Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.
&nbsp;

USANA Names Dr. Kathryn Armstrong As New Chief Scientific Officer

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and raises the price target from $35 to $38.

DA Davidson Maintains Neutral on Usana Health Sciences, Raises Price Target to $38

USANA Acquires 78.8% Stake In Hiya Health For $205M, Expanding Into Direct-To-Consumer Children's Wellness Market; Deal Expected To Add $103M In Sales And Boost 2025 Adjusted EBITDA Immediately

USANA Health Sciences shares are trading higher following mixed Q3 financial results.

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $38 to $35.

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $35

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.48 by 16.67 percent. This is a 5.08 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $200.22 million which missed the analyst consensus estimate of $205.77 million by 2.70 percent. This is a 6.16 percent decrease over sales of $213.37 million the same period last year.

Earnings Misses

Usana Health Sciences Q3 EPS $0.56 Beats $0.48 Estimate, Sales $200.22M Miss $205.77M Estimate

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) narrows FY2024 GAAP EPS guidance from $2.40-2.55 to $2.45 vs $2.50 analyst estimate. Narrows FY2024 sales outlook from $850.00 million-880.00 million to $850.00 million vs $861.94 million estimate.

Usana Health Sciences Narrows FY2024 GAAP EPS Guidance from $2.40-2.55 to $2.45 vs $2.50 Est; Narrows FY2024 Sales Guidance from $850.00M-880.00M to $850.00M vs $861.94M Est.

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is preparing to release its quarterly earnings on Tuesday, 2024-10-22. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Usana Health Sciences to report an earnings per share (EPS) of $0.48.
Investors in Usana Health Sciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.11, leading to a 3.2% drop in the share price the following trading session.
Here's a look at Usana Health Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.65</td>
<td>0.69</td>
<td>0.52</td>
<td>0.64</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.54</td>
<td>0.86</td>
<td>0.87</td>
<td>0.59</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>10.0%</td>
<td>4.0%</td>
<td>-18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729530097_0.png" alt="eps graph" />
<h3>Usana Health Sciences Share Price Analysis</h3>
Shares of Usana Health Sciences were trading at $35.85 as of October 18. Over the last 52-week period, shares are down 37.0%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/USNA/earnings">To track all earnings releases for Usana Health Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Usana Health Sciences's Quarterly Earnings

Press Releases

USANA Exec. Chairman Kevin Guest Invites All to Celebrate March's Listening Awareness Month

Entertainment

General

USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

USANA Schedules First Quarter 2025 Earnings Release and Conference Call

Clinical Study Shows USANA Celavive's Resurfacing Serum to Improve Appearance of Skin in Just Two Weeks

USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

USANA Celavive Postbiotic Rescue Serum Selected as a Good Housekeeping 2025 Beauty Award Winner

Kevin Guest Shares Transformative Success Strategies on Executive Coaching Day, May 1

USANA Releases 2024 Sustainability Report

USANA Executive Chairman Kevin Guest Celebrates National Outdoors Month with a Call to Reconnect with Nature

USANA Takes Home Five Best of State Awards, Including the Coveted Best of State Statue

Comments

Usana Health Sciences

Usana Health Sciences (USNA) Opciones

Usana Health Sciences (NYSE:USNA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL